Agilent Technologies-Here's What Key Metrics Tell Us About Agilent (A) Q2 Earnings

Core Insights - Agilent Technologies reported revenue of $1.67 billion for the quarter ended April 2025, reflecting a 6% increase year-over-year and exceeding the Zacks Consensus Estimate of$ 1.63 billion by 2.64% [1] - The company's EPS for the quarter was $1.31, up from$ 1.22 in the same quarter last year, surpassing the consensus estimate of $1.26 by 3.97% [1] Revenue Performance by End Markets - Pharmaceutical revenue reached$ 603 million, exceeding the average estimate of $572.63 million, with a year-over-year increase of 11.3% [4] - Academia and Government revenue was$ 135 million, below the average estimate of $145.13 million, representing a decline of 2.9% year-over-year [4] - Diagnostics and Clinical revenue amounted to$ 255 million, surpassing the average estimate of $247.93 million, with a year-over-year increase of 6.7% [4] - Agilent Crosslab Group net revenue was$ 713 million, exceeding the estimated $697.53 million, showing a significant year-over-year increase of 77.4% [4] - Food revenue was reported at$ 147 million, slightly above the average estimate of $146.05 million, with a year-over-year increase of 5.8% [4] - Environmental and Forensics revenue was$ 159 million, in line with the average estimate of $159.54 million, reflecting a year-over-year increase of 4.6% [4] - Chemical and advanced materials revenue was$ 369 million, slightly below the average estimate of $370.20 million, with a year-over-year increase of 1.9% [4] Stock Performance - Agilent's shares have returned +3.5% over the past month, compared to a +7.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]